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ABSTRACT
Objective: In 2001, Thailand implemented the
Universal Coverage Scheme (UCS), a public insurance
system that aimed to achieve universal access to
healthcare, including essential medicines, and to
influence primary care centres and hospitals to use
resources efficiently, via capitated payment for
outpatient services and other payment policies for
inpatient care. Our objective was to evaluate the impact
of the UCS on utilisation of medicines in Thailand for
three non-communicable diseases: cancer,
cardiovascular disease and diabetes.
Design: Interrupted time-series design, with a non-
equivalent comparison group.
Setting: Thailand, 1998–2006.
Data: Quarterly purchases of medicines from hospital
and retail pharmacies collected by IMS Health between
1998 and 2006.
Intervention: UCS implementation, April–October 2001.
Outcome measures: Total pharmaceutical sales volume
and percent market share by licensing status and National
Essential Medicine List status.
Results: The UCS was associated with long-term
increases in sales of medicines for conditions that are
typically treated in outpatient primary care settings, such
as diabetes, high cholesterol and high blood pressure, but
not for medicines for diseases that are typically treated in
secondary or tertiary care settings, such as heart failure,
arrhythmias and cancer. Although the majority of
increases in sales were for essential medicines, there were
also postpolicy increases in sales of non-essential
medicines. Immediately following the reform, there was a
significant shift in hospital sector market share by
licensing status for most classes of medicines.
Government-produced products often replaced branded
generic or generic competitors.
Conclusions: Our results suggest that expanding health
insurance coverage with a medicine benefit to the entire
Thai population increased access to medicines in primary
care. However, our study also suggests that the UCS may
have had potentially undesirable effects. Evaluations of
the long-term impacts of universal health coverage on
medicine utilisation are urgently needed.
ARTICLE SUMMARY
Article focus
▪ Medicines present a key challenge to achieving
universal coverage.
▪ Health insurance systems have the potential to
improve cost-effective use of medicines, yet
there is little evidence about their impact on
medicine use in low-income and middle-income
countries.
▪ The rapid implementation of universal health
coverage in Thailand presents a unique oppor-
tunity to measure the impact of health insurance
expansion and capitated payment on utilisation
of medicines.
Key messages
▪ Expanding health insurance coverage with a
medicines benefit to the entire Thai population
increased access to medicines in primary care.
▪ The universal coverage scheme did not seem to
have increased use of medicines for diseases
that are typically treated in secondary or tertiary
care settings, or increased generic market
penetration.
▪ In the future, it will be important for countries to
assess quality and equity of medicines use as
they pursue policies to achieve universal
coverage.
Strengths and limitations of this study
▪ We used an interrupted time-series design, the
strongest quasi-experimental approach for evalu-
ating the effects of interventions, increasing
internal validity.
▪ It is impossible to examine population sub-
groups in national IMS Health market data, but
we are reasonably confident that universal cover-
age scheme enrolees are responsible for
observed changes.
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Open Access ResearchINTRODUCTION
Universal health coverage
In 2005, member states of the World Health Organization
(WHO) made a commitment to work towards universal
healthcare coverage.
1 The 2010 WHO World Health
Report provides a roadmap for countries to achieve this
goal.
2 Universal coverage requires the restructuring of
healthcare and ﬁnancing systems to improve access to
healthcare services, reduce ﬁnancial hardship and
increase the efﬁciency and equity of the health system.
2
Medicines, which consume 25–65% of total public
and private spending on health in developing coun-
tries,
3 present a key challenge to achieving universal
coverage. The high spending on medicines, and inefﬁ-
cient use of them, threaten the ﬁnancial sustainability of
a universal coverage scheme. According to the WHO,
3 of the top 10 sources of healthcare inefﬁciency involve
medicines: high medicine prices and underuse of gener-
ics; use of substandard and counterfeit medicines; and
inappropriate and ineffective use of medicines.
2 Health
insurance systems have several features (eg, a deﬁned
population, access to utilisation data and ﬁnancial lever-
age) that give them a unique advantage to reduce
out-of-pocket (OOP) expenditures and improve the cost-
effective use of medicines through active management
strategies involving medicine selection, purchasing, con-
tracting (eg, physician payment) and utilisation manage-
ment.
4 However, there is little evidence about the
impact of health insurance on access to and use of medi-
cines in the low-income and middle-income countries
(LMICs).
4
The recent implementation of universal health cover-
age in Thailand presents a unique opportunity to
measure the impact of health insurance expansion and
hospital payment changes (the majority of the popula-
tion is now covered under a closed-ended payment
scheme
5) on utilisation of medicines.
Universal health coverage in Thailand
With the implementation of the Universal Coverage
Scheme (UCS) in 2001, Thailand became one of the
ﬁrst LMICs to achieve universal coverage.
67The reform
preserved the formal sector workforce schemes: the
Social Security Scheme (SSS) for private sector employ-
ees (7.2% of the total population in 2001) and the Civil
Service Medical Beneﬁt Scheme (CSMBS) for govern-
ment employees and their dependents (8.5%).
8 The
UCS covered those previously enrolled in a voluntary
health card scheme (20.8%), in private health insurance
(2.1%), or in a tax-based, means-tested Low Income
Scheme for the poor, elderly, children and disabled
(32.4%)
89as well as more than one-quarter (29.0%) of
the population without previous insurance.
8 The UCS
was rolled out to all provinces between April and
October 2001.
6 By 2004, 95.5% of the population was
insured, with three-quarters (75.2%) of the population
covered by the UCS.
6
In addition to coverage expansion, the reform also
dramatically altered the mechanism for hospital
payment. Before the reform, hospitals were accustomed
to fee-for-service (FFS) payments from most insurance
schemes, aside from SSS, and the uninsured, who paid
OOP per service (ie, user fees).
10 The majority of user
fee spending was on medicines.
11 After the reform, FFS
payment only applied to CSMBS patients and for the
majority of patients, now UCS enrolees, hospitals were
paid on a closed-ended basis
5 for all covered services,
including medicines.
The UCS is a compulsory, tax-ﬁnanced scheme with
comprehensive coverage of inpatient and outpatient ser-
vices, including medicines on the National List of
Essential Medicines (NLEM).
6 Individuals must enrol in
the scheme at a local Contracting Unit for Primary Care
(CUP),
6 primarily housed in government-owned hospi-
tals.
12 Each CUP receives a capitated payment per regis-
tered member to provide outpatient services and
medicines.
6 CUPs initially served as gate-keepers for sec-
ondary and tertiary hospitals. At the beginning of the
scheme, when patients were referred, diagnosis-related
payments for higher level care had to come out of the
CUP’s capitated payment, so CUPs had a ﬁnancial disin-
centive to refer patients.
6 Shortly after the reform was
implemented, a separate fund (ie, a global budget)
for inpatient services was created, which likely reduced
disincentives to refer created by the capitated payment
scheme.
6 A capitated payment also creates ﬁnancial
incentives for the use of lower cost medicines (eg, gener-
ics or less-expensive therapeutic alternatives).
Our objective was to evaluate the immediate, short-
term (1 year) and long-term (5 year) impacts of the UCS
on pharmaceutical market size and composition for med-
icines for three non-communicable diseases (NCDs):
cancer, cardiovascular disease and diabetes. We hypothe-
sised that the UCS would result in a gradual increase in
sales volume, particularly of products used in primary
care, as enrolment into the scheme increased and likely
made access to health services and medicines more
affordable for the majority of the population. We also
hypothesised that there would be an immediate shift in
market share from more expensive brand name to
less-expensive generic or branded generic products and
to medicines on the NLEM in response to closed-ended
reimbursement rules. We focused on medicines for
NCDs since these illnesses represent a large and growing
healthcare burden in Thailand
13–16 and other LMICs
17
and most, but not all, medicines for NCDs would be pre-
scribed and dispensed in primary care settings.
METHODS
Data
We used data on quarterly pharmaceutical sales in
Thailand from 1998 to 2006 provided by IMS Health.
18
The sales data are generated from reports to IMS Health
by multinational pharmaceutical companies and surveys of
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approximately 200 hospitals (including general and spe-
cialised, public and private) and 350 retail pharmacies in
Thailand. These facilities constitute a stratiﬁed random
sample of the over 1100 hospitals and 14 000 retail phar-
macies in Thailand to enable national projections.
Documentation on the IMS data collection and validation
process is available upon request from the authors.
Medicines were classiﬁed according to the European
Pharmaceutical Research Association Anatomical
Therapeutic Chemical (ATC) system.
19
Outcomes
We used two outcome measures: total volume and per
cent market share. Total volume is the number of stand-
ard units purchased per capita per quarter (ie, ‘sales’).
We analysed total volume by sector (ie, retail versus hos-
pital). A standard unit, as deﬁned by IMS Health, is the
smallest dose of a product, which equates to one tablet
or capsule for an oral dosage form, one teaspoon (5 ml)
for a syrup and one ampoule or vial for an injectable
product. For the total volume analyses, we divided total
volume by size of the population over 15 years old to
control for population growth (using yearly population
estimates from the World Bank
20). We used the entire
population as denominator for insulins, since they are
also used for type 1 diabetes, a chronic disease that
affects children. Per cent market share is the per cent of
total volume in four mutually exclusive categories of
licensing status: originator brand products, branded
generic products (products sold under a brand name
other than the originator brand name of the molecule),
generic products (products that are sold under the
generic molecule name) and products manufactured by
Thailand’s Government Pharmaceutical Organization
(GPO). We also assessed per cent market share by
NLEM status (based on the 1999 and 2004 Thai NLEM).
We analysed total volume and market share for medi-
cines in eight therapeutic classes: two classes of diabetes
products (oral antidiabetics and insulins), three classes
of cardiovascular disease products (antihypertensives,
lipid-regulating and cardiac therapy products) and three
classes of cancer products (antineoplastics, immunosti-
mulating agents and cytostatic hormone therapy pro-
ducts); table 1 in the online appendix lists all medicines
by ATC code. We assigned each therapeutic class to one
of two categories: medicines usually used to treat
primary care health conditions and medicines usually
used to treat more complicated conditions, typically in
secondary/tertiary, often inpatient care, settings.
Antidiabetic, insulin, antihypertensive and lipid-lowering
products are usually used for primary care conditions
(ie, diabetes, high blood pressure and high cholesterol),
whereas cardiac therapy and cancer products are usually
used for more severe conditions that more likely require
treatment by a specialist and/or in an inpatient setting.
Research design
We used an interrupted time-series design, the strongest
quasi-experimental approach for evaluating effects of
interventions, which has been used extensively for medica-
tion use research.
21 Although we did not have an equiva-
lent control group, we used medicines sold in the retail
sector as a non-equivalent comparison group,
22 assuming
that the retail market should be relatively unaffected by
the reforms since UCS enrolees could only obtain covered
medicines through their local, hospital-based CUP.
Statistical analysis
The intervention was the UCS roll-out from April to
October 2001. We deﬁned three distinct periods:
12-quarters prereform (1998Q2–2001Q1), a three-quarter
UCS roll-out period (2001Q2–2001Q4; grey box in
ﬁgures) and 19-quarters postreform (2002Q1–2006Q3).
Table 1 Summary of the impact of the Universal Coverage Scheme on volume of medicine sales in the hospital sector (from
segmented regression results)*
Therapeutic area Prepolicy trend Immediate change after policy Postpolicy trend change
Diabetes
Antidiabetics† ↑↑
Insulins† ↑↑ ↑
Cardiovascular disease
Antihypertensives ↑↓ ↑
Lipid-regulating agents† ↑↑
Cardiac therapy ↑↓
Cancer
Antineoplastics ↑
Cytostatic hormones ↑↑
Immunostimulating agents† ↑↓
*Arrows signify a statistically significant coefficient (p<0.05) from segmented regression with linear postpolicy trend term, unless noted
otherwise.
†Quadratic model (which has a squared postpolicy trend term) fits better than linear model.
Note: See online appendix table 2 and figures 1–8 for regression coefficients and figures for all therapeutic areas.
Garabedian LF, Ross-Degnan D, Ratanawijitrasin S, et al. BMJ Open 2012;2:e001686. doi:10.1136/bmjopen-2012-001686 3
Impact of universal coverage in Thailand on sales of medicines for NCDsWe ended analysis prior to 2006Q4 since there was a policy
change at that time (the removal of an initial 30 Baht
co-payment per visit) which may have impacted outcomes.
In sensitivity analyses, we extended the intervention
roll-out period, through 2002 and through 2003, to
account for potentially delayed implementation and lag of
actual enrolment into the scheme.
We used segmented linear regression to measure the
prereform trend, the immediate level change following
the intervention period, and the postreform change in
trend (as compared to the prereform trend). For the
NLEM analysis, we reclassiﬁed NLEM status in 2005Q1
(when the 2004 list was implemented) and included a
pre–post term (‘NLEM’) in the model to account for
possible discontinuity due to the reclassiﬁcation. We
report two estimates from the segmented regression
models—the postreform change in trend and the imme-
diate level change following the reform. We controlled
for serial autocorrelation using an autoregressive error
model. We retained all terms in the models, even if non-
signiﬁcant. We used the models to estimate absolute and
relative differences (with 95% CIs)
23 in observed versus
predicted total volume at 1 and 5 years postreform. In
sensitivity analyses, we included a quadratic term for the
postreform trend and used a likelihood ratio test to deter-
mine the best-ﬁtting model. We report below results from
the best-ﬁtting model of the shortest (ie, three-quarter)
intervention period and mention differences in model
results where they existed. Results from sensitivity analyses
are available upon request. We used the AUTOREG pro-
cedure in SAS V. 9.3 for all analyses.
RESULTS
Hospital sector volume
The majority of sales in Thailand for all cancer, cardio-
vascular disease and diabetes medicines studied were in
the hospital sector and were for medicines on the
NLEM. After implementation of the UCS, there was a
signiﬁcant increase in the level of sales of insulins and a
signiﬁcant increase in the trend in sales of antidiabetic,
insulin, antihypertensive, lipid-regulating and cytostatic
hormone products (table 1, ﬁgures 1 and 2). There was
a signiﬁcant reduction in the level of sales immediately
following the reform for three medication classes: anti-
hypertensive, cardiac therapy and immunostimulating
agents (although only the latter was signiﬁcant in the
sensitivity analyses using a longer intervention period;
table 1, ﬁgures 1 and 2).
The UCS was associated with increased sales of diabetes
medicines. One year after the policy, the sale of insulin
was 35% (95% CI 15% to 55%) higher and, at 5 years,
174% (95% CI 114% to 235%) higher than what would
have been expected in the absence of the UCS (table 2).
The increase in insulin sales was driven primarily by
human insulins, which are on the NLEM and marketed
as branded generics by two manufacturers. The policy
was associated with a 39% (95% CI 14% to 64%) increase
in antidiabetic product sales 5 years after implementation
(table 2). This was largely due to increased sales of
generic and branded generic metformin and glibencla-
mide products, both of which are on the NLEM.
Implementation of the UCS appears to have had a
mixed impact on sales of cardiovascular medicines. Five
Figure 1 Standard units per capita by quarter: insulin (hospital vs retail sector). The grey box in the figure represents the
three-quarter Universal Coverage Scheme roll-out period.
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was nearly double (108% increase; 95% CI 60% to
157%) what would have been expected in the absence
of the scheme (table 2). The increase was primarily due
to sales of branded generic simvastatin and gemﬁbrozil
products, which are on the NLEM, and a small but
steady increase in sales of originator atorvastatin pro-
ducts, which were not on the NLEM until 2004. For anti-
hypertensives, the signiﬁcant increase in postpolicy
trend compensated for an initial drop in sales, resulting
in a slight increase in sales 5 years after the policy (19%
increase; 95% CI −3% to 40%) (ﬁgure 2, table 2). The
increased trend was primarily due to the sales of enala-
pril, atenolol and amlodipine, all of which are on the
NLEM and predominately sold as branded generics.
The reform had no signiﬁcant impact on sales of
cardiac therapy medicines 1 or 5 years after the policy.
The results were also mixed for cancer medicines.
The UCS had no signiﬁcant 1-year or 5-year impact on
the sale of antineoplastics or cytostatic hormones
(although the latter class did experience a signiﬁcant
postpolicy increase in trend). However, the policy was
associated with an immediate reduction in sales of
immunostimulating agents that did not recover in the
postpolicy period. One year after implementation, the
sale of immunostimulating agents was 35% lower (95%
CI −45% to −25%) than expected from prepolicy
trends, and 26% lower (95% CI −45% to −8%) 5 years
Figure 2 Standard units per capita by quarter: antihypertensives (hospital vs retail sector). The grey box in the figure represents
the three-quarter Universal Coverage Scheme roll-out period.
Table 2 Relative impact of UCS on sales of medicines by class (1 and 5 years postpolicy)*
Therapeutic class
One-year impact (in standard units) Five-year impact (in standard units)
Predicted Observed
Relative change
(95% CI) Predicted Observed
Relative change
(95% CI)
Antidiabetics 2602.91 2769.79 6.4% (−6.9 to 19.7) 3669.13 5090.62 38.7% (13.5 to 64.0)*
Insulins 3.30 4.45 34.8% (15.1 to 54.5)* 4.58 12.56 174.4% (113.9 to 235.0)*
Cardiac therapy agents 699.28 607.27 −13.2% (−26.9 to 0.6) 908.12 825.49 −9.1% (−31.9 to 13.1)
Lipid regulating agents 522.34 504.58 −3.4% (−19.9 to 13.1) 781.97 1629.11 108.3% (59.8 to 156.9)*
Antihypertensives 3521.47 3418.79 −2.9% (−15.5 to 9.7) 5200.86 6177.49 18.8% (−2.8 to 40.3)†
Antineoplastics 35.38 34.21 −3.3% (−15.4 to 8.7) 46.14 48.13 4.3% (−16.3 to 24.9)
Cytostatic hormones 29.48 30.58 3.7% (−10.1 to 17.6) 39.82 47.52 19.3% (−5.1 to 43.8)
Immunostimulating
agents
0.65 0.43 −35.0% (−45.1 to −25.0)* 0.81 0.60 −26.3% (−45.0 to −7.6)*
*Statistically significant change (ie, CI does not include the null value of 0).
†The absolute 5-year difference, which is estimated using more precise method, is significant. See online appendix table 3.
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reduction in sales of interferon α-2b, a non-NLEM medi-
cine, around the time of UCS implementation, which
could have been due to a coincidental recall of an inter-
feron α-2b product.
24
Finally, as expected, the reform had little impact on
sales volume in the retail sector—there were few signiﬁ-
cant postimplementation changes, and the changes that
were signiﬁcant were small in magnitude (see online
appendix, table 2).
Hospital sector market share
Immediately following the reform, there were signiﬁcant
shifts in hospital sector market share by licensing status
for most classes (table 3). The changes for antidiabetics
and cardiac medicines—the two therapeutic classes with
the largest shifts—were due to signiﬁcant increases in
GPO-produced medicines, primarily at the expense of
branded generics and, to a lesser extent, generics. There
was a signiﬁcant increase in GPO antidiabetic products
(+16% of market; 95% CI 12% to 20%), and decreases
in branded generic (−12%; 95% CI −16% to −9%) and
generic (−4%; 95% CI −6t o−1%) products immedi-
ately after the policy (ﬁgure 3). Similarly, there was a sig-
niﬁcant increase in GPO cardiac therapy products
(+22%; 95% CI 15% to 28%) and signiﬁcant decreases
of branded generic (−14%; 95% CI −21% to −7%) and
generic (−4%; 95% CI −6% to −2%) products immedi-
ately after the policy (ﬁgure 4). There was also a small
decrease in market share of generic antihypertensives
(−6%; 95% CI −8% to −3%), which was compensated
for by a marginally signiﬁcant increase in GPO products.
The market for lipid-regulating agents experienced an
immediate shift from originator products (−8% market
share; 95% CI −10% to −5%) to branded generics
(+8%; 95% CI 5% to 10%). A similar shift was seen in
the market for immunostimulating agents (6% decrease
in originator products (95% CI −10% to −3%) and a
Table 3 Immediate impact of Universal Coverage Scheme on hospital sector market share*
Therapeutic area Licensing status
Immediate postpolicy absolute change
in % market share (95% CI)
Diabetes
Antidiabetics Originator brand −0.3% (−1.6 to 1.0)
Branded generic −12.3% (−16.0 to −8.7)*
Generic −3.5% (−5.8 to −1.1)*
GPO 16.1% (12.0 to 20.2)*
Insulins‡ Originator brand† −0.04% (−0.4 to 0.3)
Branded generic 7.0% (2.9 to 11.1)*
Generic −6.2% (−10.3 to −2.1)*
Cardiovascular disease
Antihypertensives Originator brand† −0.1% (−2.3 to 2.0)
Branded generic† −0.2% (−6.1 to 1.8)
Generic −5.7% (−8.3 to −3.0)*
GPO 5.3% (−0.1 to 10.6)
Lipid regulating agents Originator brand† −7.8% (−10.2 to −5.4)*
Branded generic† 7.6% (5.1 to 10.0)*
Generic 0.2% (−0.4 to 0.7)
GPO 0.2% (−0.3 to 0.8)
Cardiac therapy Originator brand 0.1% (−0.8 to 1.0)
Branded generic† −13.5% (−20.5 to −6.5)*
Generic −4.3% (−6.2 to −2.4)*
GPO 21.6% (15.0 to 28.1)*
Cancer‡
Antineoplastics Originator brand 1.1% (−1.0 to 3.2)
Branded generic −1.0% (−5.4 to 3.4)
Generic 0.4% (−2.7 to 3.4)
Cytostatic hormones Originator brand† 0.4% (−5.4 to 6.1)
Branded generic† −7.7% (−12.0 to −3.5)*
Generic† 6.0% (1.4 to 10.6)*
Immunostimulating agents Originator brand −6.4% (−9.7 to −3.0)*
Branded generic 4.5% (1.7 to 7.3)*
Generic −0.2% (−0.3 to 0.02)
*Statistically significant regression coefficient (p<0.05). Changes are in absolute terms (ie, percentage point change).
†Quadratic model (which has a squared postpolicy trend term) fits better than linear model.
‡GPO did not produce any insulins or cancer medicines during the study period.
Note 1: See online appendix table 4 and figures 9–16 for market share regression coefficients and figures for all therapeutic areas.
Note 2: Aside from the immediate level changes following the policy, there were few major changes in market share. See online appendix
table 5 for absolute 1- and 5-year differences.
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The cytostatic hormone market experienced an immedi-
ate shift from branded generic (−8%; 95% CI −12% to
−4%) to generic products (+6%, 95% CI 1% to 11%).
Generic insulins experienced a slight decrease in market
share caused by the market exit of the sole generic
manufacturer just before the policy. There were no
immediate changes in market share for antineoplastics.
Figure 4 Licensing status market share by quarter: cardiac therapy products (hospital sector). The grey box in the figure
represents the three-quarter Universal Coverage Scheme roll-out period.
Figure 3 Licensing status market share by quarter: antidiabetics (hospital sector). The grey box in the figure represents the
three-quarter Universal Coverage Scheme roll-out period.
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policy, there were few major changes in market share for
all classes.
The UCS did not have a major impact on NLEM
market share, likely because the share of NLEM medi-
cines was already quite high (see online appendix table
6 and ﬁgure 17). The only notable level change, for
immunostimulating agents, was likely due to the coinci-
dental recall of a non-NLEM interferon α-2b product.
24
Whereas all medicine classes had signiﬁcant postreform
trends, these trends were small in magnitude and NLEM
market share remained fairly stable over the study
period until the 2004 NLEM was introduced. There
were large changes in NLEM market share for three
classes—antihypertensives, lipid-regulating agents and
cytostatic hormones—at the time of the 2004 NLEM
implementation in 2005Q1 (see online appendix table 6
and ﬁgure 17). Given the increase in postreform volume
for many medicine classes, a stable NLEM market share
in the short-term (ie, pre-2005) following the UCS
implementation suggests a postreform increase in both
NLEM and non-NLEM medicines.
DISCUSSION
The UCS was associated with long-term (ie, 5 years)
increases in hospital sector sales of medicines for
chronic diseases that are usually treated in primary care
settings, such as diabetes, high blood pressure and high
cholesterol. We hypothesised this gradual increase in
volumes since the UCS expanded access to primary
care
25 and actual enrolment into the scheme occurred
gradually from implementation in 2001 until around
2004, by which time 95.5% of the population had insur-
ance coverage.
6 The UCS, which radically changed hos-
pital ﬁnancing and reimbursement, was also associated
with an immediate market shift to locally produced or
branded generic products for most therapeutic classes.
Despite these increases in access, the policy did not
appear to increase the sales of medicines for more
severe diseases like heart failure, arrhythmias and
cancer, which are often treated in secondary or tertiary
settings. This ﬁnding is consistent with evidence that the
capitated payment system initially discouraged referrals
of UCS patients to higher level care.
62 52 6The UCS also
appears to have had a mixed impact on the utilisation of
essential medicines. There were increases in NLEM
medicines, which are covered, as well as non-NLEM
medicines. Similarly, given the capitated UCS payment
system, we expected to see an increase in sales of
generic medicines, which are typically less expensive.
However, the majority of sales in most classes were for
branded generic products, many of which had generic
alternatives in the market. Interestingly, substantial
market share shifts occurred towards products manufac-
tured by the Thai GPO, which have been noted to have
higher than market prices.
27 By law, GPO products
received preferential status by hospital purchasers,
28
which negates the incentive to prescribe cheaper alter-
natives under the capitated payment system. While the
increase in GPO products and the UCS implementation
may be a coincidence in timing, it is noteworthy that the
GPO expanded its product line at a time when the UCS
policy expanded the market of people who could afford
medicines.
Our study demonstrates the value of IMS Health
market intelligence data for rigorous health policy evalu-
ation. Unlike other sources of data on pharmaceutical
utilisation (ie, national health surveys or ad hoc hospital
surveys), IMS data represent country pharmaceutical
markets consistently over time and are useful for the
evaluation of system-wide interventions. Nevertheless,
the data pose some limitations. Aggregate national sales
data do not allow us to determine whether observed
increases in medicines sales occurred preferentially
among UCS enrolees or enrolees in the SSS and CSMBS
schemes, conceivably to compensate for ﬁnancial strain
of the UCS on hospital budgets.
6 CSMBS expenditures
increased following UCS implementation
29 and
increased medicines sales among CSMBS enrolees, reim-
bursed on a fee-for-service basis, could explain increases
in non-NLEM medicines and medicines with
less-expensive therapeutic alternatives.
5 However, it is
unlikely that increased utilisation among CSMBS enro-
lees explains most of the observed volume changes since
this would imply that one-half (for diabetes) to three-
quarters (for hypertension) of CSMBS members (7.1%
of the total population in 2004
6) were on these treat-
ments in 2004. Even the CSMBS and SSS schemes com-
bined (20.3% of the total population in 2004
6)a r e
unlikely to be responsible for the observed changes
since this would imply that one-quarter (for diabetes)
and one-third (for hypertension) of enrolees in the two
schemes were on these treatments in 2004. These esti-
mates are much higher than the national prevalence
(6.7% for diabetes
30 and 22% for hypertension
31 in
2004) and unlikely in the civil servant and private sector
workforce populations, which are likely to be healthier
and wealthier than the national average.
Our interpretation of the observed changes assumes
that pharmaceutical sales to hospital and retail pharma-
cies reﬂected total market utilisation, and that hospital
sales volumes included utilisation at afﬁliated primary
care units. This assumption seems justiﬁed in light of
the estimated 91% accuracy of IMS Health data in repre-
senting the Thai pharmaceutical market.
32 For local
generic products, including those produced by the
GPO, IMS Health data are based on pharmacy surveys
only (as opposed to pharmacy surveys and manufacturer
reports), so we may have underestimated utilisation.
However, unless this systematic underestimation changed
at the point of the UCS implementation, it would not
have impacted our results. Finally, since we did not
convert standard units of product sold to deﬁned daily
doses, we do not describe sales changes in terms of
average adult doses.
8 Garabedian LF, Ross-Degnan D, Ratanawijitrasin S, et al. BMJ Open 2012;2:e001686. doi:10.1136/bmjopen-2012-001686
Impact of universal coverage in Thailand on sales of medicines for NCDsThere are also potential limitations owing to study
design and statistical analysis. We addressed the main
threat to the internal validity of the interrupted time-
series design—a concurrent event that affects the
outcome of interest—by assessing other policies or
market events that occurred at the time of the UCS,
through literature reviews, discussions with in-country
experts, and by including the retail sector as a compari-
son. The statistical approach, segmented regression ana-
lysis, usually assumes a linear trend and well-deﬁned
break point. Sensitivity analyses that varied model speci-
ﬁcation and intervention duration did not change the
ﬁndings. By reporting results from fully speciﬁed
models, we may have underestimated the statistical sig-
niﬁcance of 1-year and 5-year change estimates.
While both the context and the implementation of
universal coverage in Thailand are unique and not
necessarily generalisable to other LMICs, our ﬁndings
suggest that expanding health insurance coverage with a
medicines beneﬁt to the entire population, together
with changes in the payment system and increased local
manufacturing, increased the per capita volume of medi-
cines sold and, by inference, improved access to medi-
cines in the primary care sector in Thailand, presumably
by making medicines more affordable. Since the study
period, Thailand has enacted further policies to address
pharmaceutical sector cost escalation (eg, strict enforce-
ment of reimbursement for only NLEM medicines in
the CSMBS
33) and to ensure appropriate access to
non-NLEM medicines (eg, coverage of medicines for
HIV, renal replacement therapy and mental health con-
ditions).
34–36 In the future, it will be important for
Thailand and other countries to assess equity in access
to and quality of use of medicines, availability of medi-
cines in health centres and hospitals, out-of-pocket and
system expenditures and affordability, and health out-
comes as they pursue policies to achieve universal
coverage.
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